TY - JOUR ID - TI - The Role of Oxybutynin Chloride in the Management of Patientswith Benign Prostatic Hyperplasia فعالية عقار الاوكسيبيوتنين في علاج المرضى المصابين بتضخم البروستات الحميد AU - Nehad N. Helal AU - Rabei A. Salih AU - Mohammed M. Abdul-Azizr PY - 2008 VL - 4 IS - 1 SP - 63 EP - 68 JO - Tikrit Journal of Pharmaceutical Sciences مجلة تكريت للعلوم الصيدلانية SN - 18152716 2664231X AB - Objectives: To determine the efficacy and tolerability of Oxybutynin chloride in men with benign
prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in which previous a-blocker
therapy had failed.
Materi4ls and Methods: A total of 38 consecutive men with BPH complaining of LUTS in whom a
mean of 6.3 months of a-blocker therapy had failed received Oxybutynin (S *g twice daily orally) for 3
months in addition to the usual c-blocker medication. Primory .ifi.o.y .n-d points wlre American
Urological Association symptom score, and mean day'time and nighttime micturition frequency.
Secondaryend points were the peak urinary florv rate, post-void residual volurne, the incidence of urinary
retention, and adverse events. Statistical analysis rvas used when needed.
Rcsults: A total of 33 men (87%) lvith a mean age of 59 years complctcd the 3-month trial. Mean 24-
hour micturition frequency decreascd from ll.2 to 6.5 voids and nocturia decreased from 5.1 to 2.4
episodes nightly. Significant cltanges in mcan American Urological Association symptom scores (-
5.31), thc peak urittaty florv ratc (1.8 nrl pcr sccond) and post-vofd rcsiclual volumc (-2i ml) were also
obscrvcd. Fivc nrcn (13%) discontinucd tlrcrapy bccausc of intolerablc clry mouth. Thcrc rvere no reports
of urinary rctcntion.
Cottclttsions: Trcattttcttt rvitlt Oxybutynin in carclirlly sclcctccl rncn rvit6 Bpll alcl nroclcratc LUI'S mav
bc n rcasottablc thcrapcutic optiorr allcr ftrilcd trcatrncnt rvitlr a-blockcrs.

ER -